BioSpace Collaborative

Academic/Biomedical Research
News & Jobs
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  US Device
Europe
Asia

DIVERSITY

PROFILES
Company Profiles

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Research Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

 News | News By Subject | News by Disease News By Date | Search News
Get Our Industry eNewsletter FREE email:    
   

Luminex Corporation (LMNX) and One Lambda, Inc. Renew Long-Term Strategic Partnership


12/8/2010 7:28:48 AM

AUSTIN, Texas, Dec. 7, 2010 /PRNewswire-FirstCall/ -- Luminex Corporation (Nasdaq: LMNX) and One Lambda, Inc., the leading producer of transplant diagnostic products, have agreed to a long-term renewal of their 10-year strategic partnership aimed at developing platforms and technologies for human leukocyte antigen (HLA) typing and antibody screening for the organ transplantation market. Begun in 2000, their dedicated collaboration has resulted in the creation of innovative products that have made pre- and post-transplant diagnostics faster, and more cost-efficient.

(Logo: http://photos.prnewswire.com/prnh/20100104/LUMINEXLOGO)

"One Lambda and Luminex combined the power of Luminex's xMAP® Technology with One Lambda's expertise in HLA testing and organ transplantation to dramatically advance the care available to those undergoing transplants," said George Ayoub, president and CEO of One Lambda. "Our platforms have significantly enhanced healthcare providers' ability to care for organ transplant patients by delivering vital information that helps them to better match donors with recipients."

Effective diagnostics are essential in transplant medicine. HLA typing and antibody screening are critical in matching organ donors and organ recipients, minimizing rejection and maintaining transplant patients' long-term health following a transplant. This kind of testing can require screening a patient for hundreds of HLA markers and antibodies. One Lambda's dedication to innovation ensures their products are continually updated with the latest donor registry data and new DNA genotypes. The simplicity and flexibility of the xMAP Technology platform to analyze both nucleic acids and proteins has allowed One Lambda to enhance and expand their product menu.

"Luminex and One Lambda have set the standard for strategic partnership with our collaboration that has delivered new technology and transformed the practice of transplantation medicine," said Patrick J. Balthrop, president and CEO of Luminex. "One Lambda has an impressive history of innovation in the field of transplantation, and we expect that our work together will continue to deliver significant technology advances and market leadership into the next decade."

One Lambda adopted Luminex's xMAP Technology to create products that could reduce the cost and complexity of HLA typing and antibody screening. The xMAP platform, which allows multiple, simultaneous tests to be run on a single sample, proved to be an ideal fit for transplant testing. The flexible technology helped One Lambda to develop a range of assays that have streamlined transplant diagnostics. One Lambda's LABType® SSO and LABScreen® products can detect up to 500 HLA specificities in a single test, eliminating the need to run multiple tests. One Lambda's xMAP-based assays are used in more than 80 countries worldwide.

About One Lambda

One Lambda, Inc. is the worldwide leader in HLA typing and antibody detection assays. One Lambda is known for its commitment to quality, service, and innovation. One Lambda develops and distributes several lines of HLA typing and antibody detection tests utilizing serological, molecular, ELISA, flow, and Luminex xMAP technologies. One Lambda also manufactures laboratory instrumentation and computer software that are used to simplify and automate testing procedures and final test evaluations. For more information, please visit www.onelambda.com.

About Luminex Corporation

Luminex Corporation develops, manufactures, and markets proprietary biological testing technologies with applications throughout the diagnostic and life sciences industries. The company's xMAP® multiplex solutions include an open-architecture, multi-analyte technology platform that delivers fast, accurate, and cost-effective bioassay results to markets as diverse as pharmaceutical drug discovery, clinical diagnostics, and biomedical research, including the genomics and proteomics markets. The company's xMAP Technology is sold worldwide and is already in use in leading clinical laboratories, as well as major pharmaceutical, diagnostic, and biotechnology companies. Further information on Luminex Corporation or xMAP Technology can be obtained at www.luminexcorp.com.

Contacts:


One Lambda:


James Keegan, 818.702.0042

Chief Financial Officer


Luminex Investor Contact:


Matthew Scalo, 512.219.8020

Sr. Director Investor Relations

mscalo@luminexcorp.com


Luminex Media Contact:


Mimi Torrington, 512.219.8020

Director of Marketing Communications

mtorrington@luminexcorp.com


Aaron DeLucia, 512.241.2249

aaron.delucia@porternovelli.com



SOURCE Luminex Corporation; One Lambda, Inc.



Read at BioSpace.com

   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES
 

//-->